Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 10/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 9/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 9/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etorphine SCHEMBL25681403 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL12125405 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL15013782 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL12230551 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL140251 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL19564457 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL10031275 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL14516216 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL29381660 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL20507 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391091-B2 | Method of manufacturing buprenorphine and analogues thereof from oripavine | SIEGFRIED AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20170319574-A1 | METHOD OF MANUFACTURING BUPRENORPHINE AND ANALOGUES THEREOF FROM ORIPAVINE | SIEGFRIED AG (CH) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319574-A1 | METHOD OF MANUFACTURING BUPRENORPHINE AND ANALOGUES THEREOF FROM ORIPAVINE | OPRK1, OPRM1, OPRD1 | OPRK1 1/4885OPRM1 2/4885OPRD1 3/4885 |
| US-10391091-B2 | Method of manufacturing buprenorphine and analogues thereof from oripavine | OPRK1, OPRM1, OPRD1 | OPRK1 1/4885OPRM1 2/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.